Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib

Equality Impact Assessment (Guidance development) (PDF 157 KB)

Final draft guidance

Final appraisal document (PDF 320 KB)

Committee papers (PDF 2.25 MB)

Public committee slides (Committee meeting 6) (PDF 580 KB)

Public committee slides (Committee meeting 5) (PDF 417 KB)

Draft guidance: 3

Appraisal consultation document (PDF 366 KB)

Committee papers (PDF 3.61 MB)

Committee papers (PDF 471 KB)

Lenalidomide for treating multiple myeloma after 1 prior treatment with bortezomib (part-review of TA171): appraisal consultation

Lenalidomide for treating multiple myeloma after 1 prior treatment with bortezomib (part-review of TA171): appraisal consultation document information

Lenalidomide for treating multiple myeloma after 1 prior treatment with bortezomib (part-review of TA171): evaluation report information

Lenalidomide for treating multiple myeloma after 1 prior treatment with bortezomib (part-review of TA171): evaluation report (PDF 4.6 MB)

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): Evaluation report information

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): Evaluation report (PDF 6.58 MB)

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): final scope (PDF 34 KB)

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): final matrix (PDF 43 KB)

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): equality impact assessment - scoping (PDF 13 KB)

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): response to consultee and commentator comments on the draft scope and provisional matrix (post-referral) (PDF 94 KB)

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): draft scope (post-referral) (PDF 39 KB)

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): provisional matrix (post-referral) (PDF 43 KB)